AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
This intro covers yearly drawdown trends for total market index funds, helping readers assess risk and anticipate potential downturns.
28,238 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
XRP slipped about 10% over the past week, pushing the token toward the $1 floor as sellers dominate the chart. Analys...
The Massachusetts Supreme Judicial Court unanimously blocked a statewide rent stabilization petition from the 2026 ba...
A 65-year-old with $1.4 million outlines a three-stock income plan focused on essential networks—defense, pipelines, ...
Rivian ranks at the bottom of the JD Power 2026 Initial Quality Study, recording 246 problems per 100 vehicles in the...
PTIR's double-leveraged bet on Palantir underperformed the stock by nearly half over the past year, underscoring the ...
Google bought YouTube for $1.65 billion in 2006. The founders walked away with hundreds of millions, and today YouTub...
Strategy disclosed a new Bitcoin sale as part of its renewed capital plan. Far from signaling weakness, the move coul...
When a stock slips, smart investors look past the temporary dip. Domino's remains a dominant player with growing digi...
A veteran Jefferies strategist outlines a split AI spend cycle: upfront hardware capex drives early gains, while long...
A deep dive into a sleeper AI infrastructure stock that could gain as data centers demand faster, cleaner connectivit...
Dell shares tumbled about 14% as investors pulled back from AI hardware names, with HPE and Super Micro also sliding....